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Abstract A novel member of the human UDP-N-acetyl-D-ga-
lactosamine:polypeptide N-acetylgalactosaminyltransferase (pp-
GalNAc-T) gene family was cloned as a homolog of human pp-
GalNAc-T7, and designated pp-GalNAc-T10. pp-GalNAc-T10
transcript was found in the small intestine, stomach, pancreas,
ovary, thyroid gland and spleen. In a polypeptide GalNAc-
transfer assay, recombinant pp-GalNAc-T10 transferred Gal-
NAc onto a panel of mucin-derived peptide substrates. Further-
more, pp-GalNAc-T10 demonstrated strong transferase activity
with glycopeptide substrates.
( 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
O-Glycosylation is an important post-translational modi¢-
cation found in many secreted and membrane bound glyco-
proteins. A family of UDP-GalNAc:polypeptide N-acetyl-
galactosaminytransferases (pp-GalNAc-T, EC2.4.1.41) is
responsible for the initial step in the synthesis of mucin-type
oligosaccharides by transferring GalNAc from UDP-GalNAc
to the hydroxyl group of either a serine or threonine residue
on the polypeptide acceptor. To date, ten human pp-GalNA-
c-T isoforms (T1, T2, T3, T4, T6, T7, T8, T9, T11, and T12)
of this gene family have been cloned and characterized [1^9].
pp-GalNAc-Ts have also been identi¢ed and cloned in other
vertebrates and nematodes [10^17]. Analysis of mammalian
pp-GalNAc-Ts has demonstrated that di¡erent isoforms
have di¡erent kinetic properties and unique substrate speci¢c-
ities for substrates such as tandem repeat regions of mucins
[3,12,15,18], although there are substantial overlaps, too. Evi-
dence is accumulating that the substrate speci¢city of pp-Gal-
NAc-T is the major factor determining the sites and density of
O-glycan attachments on peptide backbones [18]. In addition
to having di¡erent catalytic properties, each isoform has a
di¡erent expression pro¢le. The di¡erential expression of pp-
GalNAc-Ts in cells and tissues may control the O-glycosyla-
tion mechanisms. However, the exact molecular processes
governing the speci¢city and the kinetics of O-glycosylation
remain unclear. The cloning and characterization of novel pp-
GalNAc-Ts will help our understanding of the O-glycosyla-
tion process.
In the present study, we report the cloning and character-
ization of another member of this polypeptide GalNAc-trans-
ferase family, pp-GalNAc-T10. During this study, rat pp-Gal-
NAc-T9, which shares high homology with human pp-
GalNAc-T10, was cloned and analyzed [16]. However, unlike
rat pp-GalNAc-T9, which exhibited no GalNAc-transferase
activity toward non-glycosylated peptides [16], human pp-
GalNAc-T10 apparently displayed catalytic activity toward
non-glycosylated peptides in addition to strong activity for
glycosylated peptides.
2. Materials and methods
2.1. Cloning of pp-GalNAc-T10 cDNA
A BLAST search of expressed sequence tag databases identi¢ed ¢ve
cDNAs (GenBank accession numbers: BG772195, BF359671,
BF359677, BF359680, and AK023782) as homologs of human pp-
GalNAc-T7 (AJ002744). A full-length open reading frame (ORF) of
a novel polypeptide GalNAc transferase was identi¢ed by database
gene walking. The cDNA encoding the full-length ORF was obtained
by polymerase chain reaction (PCR) using the Expand1 High Fidelity
PCR system (Roche), the cDNA of a human colon cancer cell line
(Colo205) as a template, and the primers 5P-GGGGACAAGTTTGT-
ACAAAAAAGCAGGCTTCGAAGGAGATAGAACCATGAGGC-
GGAAGGAGAAGCGGCTC-3P (forward) and 5P-GG GGACCA-
CTTTGTACAAGAAAGCTGGGTCTCAGTTCTATTGAATTTTT-
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CCAA-3P (reverse). These primers have an attB1 or attB2 overhang to
create recombination sites. The ampli¢ed fragment was subcloned into
the vector pDONR2011 using the BP CLONASE Enzyme Mix (In-
vitrogen). The sequences of subcloned cDNA were determined using
the DYEnamic1 DNA sequencing kit (Amersham Pharmacia Bio-
tech).
2.2. Quantitative analysis of the pp-GalNAc-T10 transcripts in human
tissues by real-time PCR
Marathon ready0 cDNAs of various human tissues were purchased
from CLONTECH. The primer set and the probe for pp-GalNAc-T10
were as follows: the forward primer, 5P-CGCGTAGGAAATGGA-
GAACAA-3P ; the reverse primer, 5P-TCGGTATGCCTGATCCA-
CTCT-3P ; and the probe, 5P-AGACCTTACCCCATGACCGAT-
GCTGA-3P. Standard curves were generated by the methods de-
scribed previously [19]. PCR was carried out using the TaqMan Uni-
versal PCR Master Mix (Applied Biosystems), primers, probe, and
cDNAs. PCR products were continuously measured with the ABI
PRISM 7700 Sequence Detection System (Applied Biosystems). The
relative amount of pp-GalNAc-T10 transcript was normalized to the
amount of human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) transcript in each cDNA.
2.3. Production and puri¢cation of recombinant pp-GalNAc-T10
protein with FLAG peptide tag
The cDNA fragment encoding the putative catalytic domain of pp-
GalNAc-T10 (amino acids 35^604) was ampli¢ed by PCR using the
primers 5P-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCCA-
GCCCGACGGCACCCCTGGGGGA-3P (forward), 5P-GGGGACC-
ACTTTGTACAAGAAAGCTGGGTCTCAGTTCCTATTGAATT-
TTTCCAA-3P (reverse). The ampli¢ed fragment was cloned into
pDONR2011, and subcloned into the expression vector pFBIF using
the LR CLONASE enzyme mix (Invitrogen) [9,19]. Bacmid DNA was
isolated from the DH10BAC competent cells (the BAC to BAC Bacu-
lovirus Expression Systems, Invitrogen) that were transformed with
the pFBIF containing the pp-GalNAc-T10 catalytic domain. The bac-
mid was transfected into Sf21 cells (Pharmingen, San Diego, CA,
USA) to yield conditioned medium containing recombinant pp-Gal-
NAc-T10 protein. The secreted recombinant pp-GalNAc-T10 protein
was puri¢ed using anti-FLAG M1 antibody-conjugated resin (Sigma).
The puri¢ed pp-GalNAc-T10 protein was separated by 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS^PAGE), and
analyzed by Western blotting using anti-FLAG M2 (Sigma) and the
enhanced chemiluminescence-plus (ECLþ) Western blot detection kit
(Amersham Biosciences).
The soluble forms of recombinant pp-GalNAc-T2 and -T6, contain-
ing amino acid residues 52-571(T2) and 83-622(T6), respectively [1,4],
were also generated, puri¢ed, and quanti¢ed by the same methods as
for pp-GalNAc-T10.
2.4. Analysis of pp-GalNAc-T10 activity
Standard assays for pp-GalNAc-T10 activity were performed by the
incubation of 20 Wl of total reaction mixture containing 25 mM Tris^
HCl (pH7.4), 5 mM MnCl2, 0.2% Triton X-100, 0.25 mM UDP-Gal-
NAc (Sigma), 50 pmol acceptor substrate peptide labeled with 5-car-
boxy£uorescein succinimidyl ester (FAM), and the adequate amount
of puri¢ed recombinant pp-GalNAc-T10 or -T6. After incubation for
various periods at 37‡C, the reaction was stopped by boiling samples
for 3 min. Then, the reaction mixture was injected onto a C18 reverse
column (water 5C18^AR, 4.6U250 mm) in high-performance liquid
chromatography (HPLC; Shimadzu, Kyoto, Japan). The reaction
products were eluted with a gradient (0^50%) of acetonitrile contain-
ing 0.05% tri£uoroacetic acid (TFA) at a £ow rate of 1.0 ml/min at
40‡C, and monitored with a £uorescence spectrophotometer. FAM-
labeled peptide substrates: Muc1a (AHGVTSAPDTR), Muc2(PTTT-
PITTTTTVTPTPTPTGTQTK), Muc5AC (GTTPSPVPTTSTTSA),
Muc7 (PTPSATTPAPPSSSAPPETTAAK), and EA2 (PTTDSTTPA-
PTTK), which were derived from the tandem repeat domains of cor-
responding mucins [20^24], were purchased from Sawady (Tokyo,
Japan). The mono-glycopeptide substrates were prepared by the in-
cubation of the EA2 or Muc5AC peptide with pp-GalNAc-T2, fol-
lowed by the puri¢cation with HPLC, and were analyzed by mass
spectrometry.
2.5. Mass spectrometry
Mass spectrometry was performed by matrix-assisted laser desorp-
tion/ionization time-of-£ight (MALDI-TOF). To determine the num-
ber of GalNAcs that were transferred to the EA2 peptides by pp-
GalNAc-T10, or by -T6, the reaction products were isolated and
puri¢ed by HPLC. The puri¢ed fractions were dried, redissolved in
distilled water, mixed with the same amount of matrix solution
(K-cyano-4-hydroxycinnamic acid, saturated in 30% acetonitrile con-
taining 0.1% TFA), and subjected to MALDI-TOF mass spectrome-
try using REFLEX1 IV (Bruker Daltonics, Tsukuba, Japan).
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Fig. 1. A: Nucleotide and predicted amino acid sequences of pp-GalNAc-T10. Numbering of the cDNA begins with the initiation codon. The
predicted amino-acid sequence was presented under its putative nucleotide coding sequence. The triangle represents the starting position of the
truncated form. The predicted transmembrane domain is underlined with a single solid line, the GT1 motif is boxed, the Gal/GalNAc-T motif
is underlined with a dashed line, and the lectin-like domain is represented by a double line. B: A phylogenetic tree of pp-GalNAc-Ts. A phylo-
genetic tree of pp-GalNAc-Ts was constructed by the neighbor-joining method [34], based on the amino acid sequences. The branch length in-
dicates the evolutionary distance.
Fig. 2. Quantitative analysis of pp-GalNAc-T10 transcripts in various human tissues by real-time PCR. Expression levels of transcripts are
shown as a bar chart. Values are demonstrated as copy numbers of the target gene in 1 Wg of total RNA. Data were obtained from triplicate
experiments and are indicated as the meanSS.D.
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3. Results and discussion
In an e¡ort to further understand the diverse pp-GalNAc-T
family, we cloned a novel isoform and designated it pp-Gal-
NAc-T10. As shown in Fig. 1A, the cDNA contains an 1812-
bp ORF encoding a type II membrane protein with 603 amino
acids. Within the catalytic domain, pp-GalNAc-T10 contains
the conserved GT1 and Gal/GalNAc-T motifs, which are pu-
tative binding sites for both an UDP-sugar and an acceptor.
At the C-terminus, the cloned isozyme contains a lectin-like
domain, a potential carbohydrate recognition domain. A lec-
tin-like domain is observed only in pp-GalNAc-Ts among
glycosyltransferase families [3,25,26].
In the phylogenetic tree (Fig. 1B), pp-GalNAc-T10 is posi-
tioned in the subfamily of ¢ve pp-GalNAc-Ts, including rat
pp-GalNAc-T9, and human, rat and mouse pp-GalNAc-T7.
pp-GalNAc-T10 shares 94% amino-acid homology with rat
pp-GalNAc-T9, suggesting that rat pp-GalNAc-T9 is an or-
thologous isoform of pp-GalNAc-T10.
The expression levels of the pp-GalNAc-T10 transcript in
various human tissues were examined using quantitative real-
time PCR. pp-GalNAc-T10 was expressed in all tissues tested,
Fig. 3. A: HPLC analysis of in vitro O-glycosylation toward a panel of peptide substrates by pp-GalNAc-T10. The elution pro¢les of the origi-
nal peptide substrates (S) and the reaction products (P), which were generated by pp-GalNAc-T10. B: HPLC analysis of the in vitro O-glyco-
sylation toward Muc1a by pp-GalNAc-T10 and -T6. Panels a and b show the elution pro¢les of the Muc1a peptide glycosylated by pp-Gal-
NAc-T10 and -T6, respectively. Peak S corresponds to the original substrate. Peak P corresponds to the products of the enzyme reaction. The
incubation time is indicated on the right side of the panel. C: HPLC analysis of the in vitro O-glycosylation toward the EA2 peptide by pp-
GalNAc-T10 and -T6. Panels a and b show the elution pro¢les of the EA2 peptide glycosylated by pp-GalNAc-T10 and -T6, respectively. Peak
S corresponds to the original substrate, EA2 peptide. Peaks P1^P5 correspond to the products generated by pp-GalNAc-T10. Peaks P1P and
P2P correspond to the products generated by the pp-GalNAc-T6. The incubation time is indicated on the right sides of the panels. D: HPLC
and MALDI-TOF (MS) pro¢les of EA2 peptide substrate and reaction products generated by pp-GalNAc-T10 and -T6. Panel a shows the elu-
tion pro¢les of the parent EA2 peptide (S) and reaction products generated by pp-GalNAc-T10 (P1 to P5) and -T6 (P1P to P2P). Panel b shows
MALDI-TOF mass spectra for each isolated peak. Mono, di, tri, tetra represent one, two, three, four GalNAc-glycopeptide, respectively.
E: HPLC analysis of the glycosylation of EA2 peptide and the mono-GalNAc-EA2 glycopeptide generated by pp-GalNAc-T10. SQ corresponds
to the mono GalNAc-EA2 that was used as a glycopeptide substrate. P1Q, P2Q and P3Q correspond to the products generated by pp-GalNAc-
T10 from the mono-GalNAc-EA2.
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although the expression levels were di¡erent depending on the
tissues (Fig. 2). The highest level of transcript was found in
the small intestine, while intermediate levels were seen in the
stomach, pancreas, ovary, thyroid gland and spleen. Lower
levels to trace amounts were observed in other tissues exam-
ined. Human pp-GalNAc-T isoforms, i.e. pp-GalNAc-T1,
-T2, -T4, -T7 and -T8, were also ubiquitously expressed
[1,3,5,6]. The reasons why multiple pp-GalNAc-Ts are ex-
pressed within a single tissue are still unclear. Because pp-
GalNAc-Ts have speci¢c target substrates [18,27,28], there
may be competition and coordination among pp-GalNAc-Ts
for the appropriate glycosylation of acceptor substrates in a
cell. Thus, the expression of multiple pp-GalNAc-Ts within a
tissue may be necessary for the serial glycosylation of sub-
strate proteins by pp-GalNAc-Ts, or may provide redundancy
to ensure protein glycosylation.
The expression level of the pp-GalNAc-T10 transcript was
low in most tumor cell lines examined (data not shown), and
we could not ¢nd a speci¢c expression pattern among cell
lines.
To analyze pp-GalNAc-T10 activity in vitro, the recombi-
nant pp-GalNAc-T10 fused with the FLAG-epitope peptide
was puri¢ed from the conditioned medium of the transfected
Sf21 cells by a⁄nity chromatograph with anti-FLAG M1-
conjugated resin. The puri¢ed protein was quanti¢ed by West-
ern blotting with anti-FLAG mAb, and used for enzyme as-
Fig. 3 (Continued).
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says. The puri¢ed recombinant pp-GalNAc-T10, UDP-Gal-
NAc, and a panel of acceptor substrates were incubated for
various time periods, and the reaction products were analyzed
by HPLC.
First, we analyzed the catalytic activities of pp-GalNAc-
T10 toward peptide substrates derived from Muc1, Muc2,
Muc5AC, Muc7, and EA2. As demonstrated in Fig. 3A, pp-
GalNAc-T10 generated product peaks (P) that were shifted
from substrate peaks (S) with the Muc1a, Muc5AC, Muc7,
and EA2 peptide, but negligible activity toward Muc2. These
data indicate that pp-GalNAc-T10 has signi¢cant pp-Gal-
NAc-T activity toward the mucin-derived peptides.
To assess the strength of the catalytic activity of pp-Gal-
NAc-T10, we incubated the Muc1a peptide with pp-GalNAc-
T10 or -T6 for varying periods and analyzed the reaction
mixture by HPLC. As shown in Fig. 3B, both pp-GalNAc-
T10 and -T6 e¡ectively utilized the Muc1a peptide (shown as
‘S’) and yielded one product peak, ‘P’, even after extended
incubation. The amount of the substrate remaining after 1 h
incubation with pp-GalNAc-T10 was almost the same as that
of 10 min incubation with pp-GalNAc-T6. Thus, in this ex-
periment, the activity of pp-GalNAc-T10 toward the Muc1a
peptide was one-sixth of that of pp-GalNAc-T6, which has
strong GalNAc-transfer activity with the Muc1a peptide [4].
The EA2 peptide, which contains seven potential glycosyl-
ation sites, was derived from the tandem repeats of the rat
submandibular gland mucin. The incubation of the EA2 pep-
tide with pp-GalNAc-T10 generated multiple product peaks
with a unique pattern on HPLC pro¢le (panel a in Fig. 3C).
The product peaks P1 and P2, which were the closest to the
original substrate peak, were very small in any incubation
period, whereas peaks P3, P4 and P5, re£ecting more heavily
glycosylated peptides, gradually appeared but became higher
than P1 and P2. In contrast, a product peak, P1P, that was
generated by pp-GalNAc-T6, was the only peak in the initial
reaction period, and then P1P was gradually consumed and
the subsequent product peak, P2P, appeared as incubation
extended (panel b in Fig. 3C). The retention time of P2 was
the same as that of P1P, while the retention time of P3 was the
same as that of P2P (also demonstrated in panel a in Fig. 3D).
Because these results suggested that pp-GalNAc-T10 trans-
ferred multiple GalNAcs to the EA2 peptide, we wanted to
determine the numbers of GalNAcs transferred to the EA2
peptide by pp-GalNAc-T10 or -T6. For this purpose, we pu-
ri¢ed product peaks by HPLC and subjected the puri¢ed frac-
tions to the mass spectrometry. As shown in panel b of Fig.
3D, the determined molecular weights of the products corre-
sponding to peaks P3, P4, P5 (generated by T10), P1P, and P2P
(generated by T6) matched the expected molecular weights of
the FAM-labeled EA2 with di-, tri-, tetra-, and mono-, di-
GalNAc residues, respectively. Unfortunately, we could not
fractionate su⁄cient amounts of peaks P1 and P2 for mass
spectrometry. However, because the retention times of P2 and
P1P were the same, the results strongly suggested that both P1
and P2 peaks represented mono-GalNAc-attached EA2 pep-
tides, presumably at di¡erent sites. Taken together, our results
indicated that pp-GalNAc-T10 ¢rst transfers one GalNAc to
a Thr or Ser site in the EA2 peptide in a less e⁄cient fashion,
and then transfers another GalNAc immediately to the other
sites, suggesting that GalNAc-T10 had strong pp-GalNAc-T
activity toward the glycosylated EA2 and relatively weak pp-
GalNAc-T activity toward the EA2 peptide.
To further analyze the substrate speci¢city of pp-GalNAc-
T10, we prepared the mono-GalNAc EA2 glycopeptide and
used it as an acceptor substrate. As shown in Fig. 3E, a
product peak P1Q appeared soon after a short incubation
with GalNAc-T10, while the substrate peak SQ was rapidly
consumed. Then, P1Q was gradually consumed and the other
product peaks, P2Q and P3Q, appeared as incubation extended.
The amount of the EA2 substrate remaining after the Gal-
NAc-T10 enzyme reaction for 8 h was almost the same as that
of the GalNAc-EA2 substrate remaining after the enzyme
 
Fig. 3 (Continued).
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reaction for only 10 min, indicating that pp-GalNAc-T10
showed more preferential activity for the mono-GalNAc-
EA2 glycopeptide than for the EA2 peptide. Several studies
have demonstrated relative e¡ects, negative as well as positive,
of adjacent and distant O-glycans on the kinetics of subse-
quent in vitro O-glycosylation [16,29,30]. The addition of a
GalNAc to the EA2 peptide may induce conformational
changes of the peptide that in£uence the accessibility of par-
ticular acceptor sites for pp-GalNAc-T10. Previous publica-
tions have identi¢ed the e¡ects of O-glycosylation on peptide
backbone conformation near the glycosylation sites as well as
at distant sites [31^33]. Another possible mechanism is that
the lectin domain of pp-GalNAc-T10 binds to the peptide-
attached GalNAc and contributes to the glycosylation of the
GalNAc-EA2 glycopeptide by pp-GalNAc-T10, which is a
similar mechanism found in human pp-GalNAc-T4 [25].
pp-GalNAc-T10 exhibited strong GalNAc-transferase activ-
ity toward the mono-GalNAc-Muc5AC glycopeptide, too
(data not shown).
pp-GalNAc-T10 shares 94% amino acid sequence homology
with rat pp-GalNAc-T9, suggesting human pp-GalNAc-T10 is
an orthologous isoform of rat pp-GalNAc-T9. However, hu-
man pp-GalNAc-T10 and rat pp-GalNAc-T9 are di¡erent in
substrate speci¢cities. It was reported that rat pp-GalNAc-T9
did not transfer a GalNAc to unmodi¢ed peptide substrates,
including Muc1, EA2, Muc2, and Muc5AC[16], but human
pp-GalNAc-T10 showed clear catalytic activity toward a pan-
el of unmodi¢ed polypeptide substrates. Both pp-GalNAc-
T10 and rat pp-GalNAc-T9 demonstrated strong pp-Gal-
NAc-T activity toward EA2 and Muc5AC glycopeptides.
In conclusion, the present study provides evidence that hu-
man pp-GalNAc-T10 is a new member of the pp-GalNAc-T
family. The broad expression and unique acceptor substrate
speci¢city suggest that pp-GalNAc-T10 may play important
roles in O-glycosylation.
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